Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 122 articles:
HTML format



Single Articles


    August 2026
  1. CAO S, Liu M, Wang C, Yang S, et al
    Nonsteroidal anti-inflammatory drug use and site-specific risk of urological cancers: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1471.
    PubMed     Abstract available


  2. ISHIMOTO K, Narita T, Sekine Y, Shinohara M, et al
    Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma.
    BMC Cancer. 2026;26:1470.
    PubMed     Abstract available


  3. PARVIZIFARA S, Angaji SA, Beikzadeh B, Narouie B, et al
    CD22 and CD79A expression level in bladder cancer patients using bioinformatics tools, RNA-Seq and qRT-PCR validation.
    BMC Cancer. 2026;26:1419.
    PubMed     Abstract available


  4. ZHENG W, Yao C, Wang Z, Zhang C, et al
    The predictive value of PD-1 for the response to immune checkpoint inhibitor therapy in patients with bladder cancer without lymph node metastasis and its association with survival outcomes.
    BMC Cancer. 2026;26:1348.
    PubMed     Abstract available


  5. HAO WP, Lin ZB, Ke L, Liu HJ, et al
    Overexpression of small nucleolar RNA host gene family members predicts poor bladder cancer prognosis: based on a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1324.
    PubMed     Abstract available


    July 2026
  6. SAKAI R, Shimada H, Hata S, Yokoyama A, et al
    Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells.
    BMC Cancer. 2026;26:1283.
    PubMed     Abstract available


  7. KURAL S, Kumar L, Pathak AK, Singh S, et al
    Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
    BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
    PubMed     Abstract available


  8. MOHANTY P, Subhangini M
    Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
    PubMed     Abstract available


    June 2026
  9. HAO X, Ye C, Lai W, Xu J, et al
    Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
    BMC Cancer. 2026;26:805.
    PubMed     Abstract available


  10. YI L, Ma Z, Zhang J, Zhan Y, et al
    A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
    PubMed     Abstract available


  11. ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
    ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
    PubMed     Abstract available


  12. HU P, Wang C, Zeng X, Jin S, et al
    The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
    PubMed     Abstract available


  13. WANG T, Jiang X
    Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
    BMC Cancer. 2026;26:997.
    PubMed     Abstract available


  14. TAMBARO R, Calvanese G, Muto A, Formisano L, et al
    Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
    BMC Cancer. 2026;26:956.
    PubMed     Abstract available


    May 2026
  15. CHEN C, Liu X, Xu A, Jiang N, et al
    Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
    PubMed     Abstract available


  16. WANG Y, Ailiyaer A, Chen S, Wang W, et al
    Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
    BMC Cancer. 2026;26:813.
    PubMed     Abstract available


    April 2026
  17. RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
    Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
    BMC Cancer. 2026;26:756.
    PubMed     Abstract available


  18. WU Q, Lu P, Zhang X, Qing X, et al
    Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
    BMC Cancer. 2026;26:680.
    PubMed     Abstract available


  19. TANUMA K, Shiga M, Sano K, Hamada K, et al
    Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
    PubMed    


    March 2026
  20. KIM JH, Maeng S, Choi J, Lee CU, et al
    The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
    PubMed    


  21. HUO X, Qi J, Zhu Y, Song H, et al
    Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
    BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
    PubMed    


  22. FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
    Mumio and bladder cancer: unlocking its potential in 3D cell culture.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
    PubMed    


    February 2026
  23. ZHANG L, Cao J, Gao Z, Han C, et al
    Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
    PubMed    


  24. GAO WB, Yu JJ
    Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
    PubMed    


  25. ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
    Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
    PubMed     Abstract available


  26. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
    BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
    PubMed    


  27. OSAKA K, Kishida T, Umemoto S, Karashima T, et al
    Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
    BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
    PubMed    


    January 2026
  28. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
    Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
    PubMed     Abstract available


    December 2025
  29. BLONDEAU A, Pitout A, Manuguerra A, Eschwege P, et al
    Sarcopenia measured by artificial intelligence as a predictor of overall survival in localized bladder cancer, a multicenter study.
    BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15363.
    PubMed     Abstract available


  30. LAN K, Zhang Y, Luo Y, Hong T, et al
    Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15359.
    PubMed     Abstract available


  31. DU C, Wei W, Hu M, He J, et al
    Enhancing prediction accuracy for muscle invasion in bladder cancer using a dual-energy CT-based interpretable model incorporating habitat radiomics and deep learning.
    BMC Cancer. 2025;25:1842.
    PubMed     Abstract available


    November 2025
  32. YANG IN, Liang CA, Wu CC, Xu QS, et al
    Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
    BMC Cancer. 2025;25:1900.
    PubMed     Abstract available


  33. ZHAO Y, Li P, Shen Z, Yao S, et al
    Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
    BMC Cancer. 2025;25:1796.
    PubMed     Abstract available


  34. LEE SY, Lee YH, Kim TM, Ha US, et al
    TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study.
    BMC Cancer. 2025;25:1735.
    PubMed     Abstract available


  35. HU D, Liu H, Li M, Wu W, et al
    Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study.
    BMC Cancer. 2025;25:1719.
    PubMed     Abstract available


  36. ZHAO Y, Ji Z, Sun W, Liu X, et al
    Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:1702.
    PubMed     Abstract available


    October 2025
  37. ZHENG J, Lu S, Zhang Q, Zhang L, et al
    Development and external validation of a FISH-clinical nomogram for predicting overall survival in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2025;25:1648.
    PubMed     Abstract available


  38. FANG C, Huang X, Dai J, He W, et al
    Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2025;25:1613.
    PubMed    


  39. LI W, Shi Y, Pu L, Zhang J, et al
    Shared decision-making in urinary reconstruction among radical cystectomy patients: a thematic analysis of patient and provider perspectives in China.
    BMC Cancer. 2025;25:1590.
    PubMed     Abstract available


  40. YEH CC, Tsai PC, Song YD, Low YS, et al
    Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model.
    BMC Cancer. 2025;25:1534.
    PubMed     Abstract available


  41. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al
    Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.
    BMC Cancer. 2025;25:1525.
    PubMed     Abstract available


  42. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al
    Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.
    BMC Cancer. 2025;25:1524.
    PubMed     Abstract available


  43. CHEN B, Zhou Y, Li Z, Chen J, et al
    A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
    BMC Cancer. 2025;25:1497.
    PubMed    


    September 2025
  44. LIU S, Lei K, Li G, Zheng P, et al
    The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
    BMC Cancer. 2025;25:1463.
    PubMed     Abstract available


  45. ZHANG J, Cheng X, Huang C, Xu Y, et al
    The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
    BMC Cancer. 2025;25:1460.
    PubMed     Abstract available


  46. LI C, Liu J, Wang L, Xiong W, et al
    Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
    BMC Cancer. 2025;25:1404.
    PubMed     Abstract available


    July 2025
  47. RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
    Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
    BMC Cancer. 2025;25:1227.
    PubMed     Abstract available


  48. LI J, Liang J, Xu Y, Tan W, et al
    Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.
    BMC Cancer. 2025;25:1211.
    PubMed     Abstract available


  49. WANG B, Gong Z, Su P, Zhen G, et al
    Multi-machine learning model based on radiomics features to predict prognosis of muscle-invasive bladder cancer.
    BMC Cancer. 2025;25:1116.
    PubMed     Abstract available


  50. HUANG L, Yan D, Ruan H, Lin Q, et al
    BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
    BMC Cancer. 2025;25:1057.
    PubMed     Abstract available


    June 2025
  51. PAN Y, Shih HJ, Chuang SH, Chang CP, et al
    Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.
    BMC Cancer. 2025;25:980.
    PubMed     Abstract available


    May 2025
  52. XU M, Zhou J, Lv J, Zhang Y, et al
    Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.
    BMC Cancer. 2025;25:932.
    PubMed     Abstract available


  53. N S, Ps H, P R, Paul L, et al
    Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer.
    BMC Cancer. 2025;25:916.
    PubMed     Abstract available


  54. LAN T, Zhu Y, Zhong W, Tan Q, et al
    Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.
    BMC Cancer. 2025;25:868.
    PubMed     Abstract available


    April 2025
  55. WANG X, Qu Y, Sun Y, Yang T, et al
    ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
    BMC Cancer. 2025;25:789.
    PubMed     Abstract available


  56. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    PubMed     Abstract available


  57. QIU H, Deng X, Zha J, Wu L, et al
    Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer.
    BMC Cancer. 2025;25:717.
    PubMed     Abstract available


  58. LI Z, Su M, Li Q, Zheng X, et al
    The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.
    BMC Cancer. 2025;25:714.
    PubMed     Abstract available


  59. PLAGE H, Ahlburg V, Hofbauer S, Furlano K, et al
    Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.
    BMC Cancer. 2025;25:677.
    PubMed     Abstract available


    March 2025
  60. YANG H, Zhang T, Li Z, Cai Y, et al
    Risk factors for in-hospital venous thromboembolism in patients with bladder cancer: A retrospective single-center study.
    BMC Cancer. 2025;25:536.
    PubMed     Abstract available


  61. WAN S, Li KP, Chen SY, Wang CY, et al
    Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
    BMC Cancer. 2025;25:533.
    PubMed     Abstract available


  62. DAI L, Ye K, Yao G, Lin J, et al
    Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.
    BMC Cancer. 2025;25:523.
    PubMed     Abstract available


  63. SHENG Z, Xu J, Wang M, Xu X, et al
    The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
    BMC Cancer. 2025;25:468.
    PubMed     Abstract available


    February 2025
  64. CAI J, Yan Z, Zhong Y, Li Y, et al
    Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:319.
    PubMed     Abstract available


  65. ZHENG Z, Dai F, Liu J, Zhang Y, et al
    Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer.
    BMC Cancer. 2025;25:310.
    PubMed     Abstract available


  66. YAN L, Liang H, Qi T, Deng D, et al
    Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    BMC Cancer. 2025;25:297.
    PubMed     Abstract available


  67. WANG C, Li K, Huang R, Wan S, et al
    Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.
    BMC Cancer. 2025;25:271.
    PubMed     Abstract available


  68. LI Z, Wang Z, Wu J, Zhang F, et al
    Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.
    BMC Cancer. 2025;25:268.
    PubMed     Abstract available


  69. LI KP, Wan S, Wang CY, Chen SY, et al
    Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression.
    BMC Cancer. 2025;25:234.
    PubMed     Abstract available


  70. LI P, Jing S, Kang Y, Feng B, et al
    Clinical outcomes of nephroureterectomy with bladder cuff excision or radical cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
    BMC Cancer. 2025;25:221.
    PubMed     Abstract available


  71. FURUKAWA J, Kakei Y, Murakami S, Kita H, et al
    Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.
    BMC Cancer. 2025;25:195.
    PubMed     Abstract available


    January 2025
  72. CHEN T, Zou X, Li Y, Peng L, et al
    Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
    BMC Cancer. 2025;25:135.
    PubMed     Abstract available


    November 2024
  73. SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
    Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
    BMC Cancer. 2024;24:1444.
    PubMed     Abstract available


    October 2024
  74. FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
    BMC Cancer. 2024;24:1333.
    PubMed     Abstract available


  75. KARLSSON P, Nygren-Bonnier M, Torikka S, Porserud A, et al
    Patients experiences of an exercise intervention in primary care following robot-assisted radical cystectomy due to bladder cancer: a qualitative study.
    BMC Cancer. 2024;24:1306.
    PubMed     Abstract available


  76. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    PubMed     Abstract available


  77. YAO Z, Li Y, Ding Y, Hou Y, et al
    Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study.
    BMC Cancer. 2024;24:1239.
    PubMed     Abstract available


    September 2024
  78. PALACKA P, Holickova A, Roska J, Makovicky P, et al
    Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.
    BMC Cancer. 2024;24:1103.
    PubMed     Abstract available


    August 2024
  79. FAN Z, Liu Y, Wang X, Xu Y, et al
    APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.
    BMC Cancer. 2024;24:1046.
    PubMed     Abstract available


  80. CHEN D, Cao H, Zheng X, Wang H, et al
    Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    BMC Cancer. 2024;24:1024.
    PubMed     Abstract available


  81. BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
    Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
    BMC Cancer. 2024;24:971.
    PubMed     Abstract available


  82. HAO S, Yang Z, Wang G, Cai G, et al
    Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:958.
    PubMed     Abstract available


  83. LIU R, Yang T, Huang J, Xiao Z, et al
    Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:947.
    PubMed     Abstract available


    July 2024
  84. CICIN I, Plimack ER, Gurney H, Leibowitz R, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
    BMC Cancer. 2024;23.
    PubMed     Abstract available


  85. PORSERUD A, Karlsson P, Aly M, Rydwik E, et al
    Effects of an exercise intervention in primary care after robot-assisted radical cystectomy for urinary bladder cancer: a randomised controlled trial.
    BMC Cancer. 2024;24:891.
    PubMed     Abstract available


  86. IQBAL MS, Sardar N, Peng K, Almutairi LA, et al
    Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.
    BMC Cancer. 2024;24:880.
    PubMed     Abstract available


  87. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
    Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
    BMC Cancer. 2024;24:839.
    PubMed     Abstract available


    June 2024
  88. ZHANG X, Hong B, Li H, Zhao J, et al
    Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:746.
    PubMed     Abstract available


  89. MENG H, Yang R, Lin Q, Du W, et al
    Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
    BMC Cancer. 2024;24:737.
    PubMed     Abstract available


  90. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    PubMed     Abstract available


    March 2024
  91. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    PubMed     Abstract available


    February 2024
  92. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    PubMed     Abstract available


  93. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    PubMed     Abstract available


  94. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    PubMed     Abstract available


    January 2024
  95. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    PubMed     Abstract available


  96. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    PubMed     Abstract available


  97. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    PubMed     Abstract available


    November 2023
  98. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    PubMed     Abstract available


  99. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    PubMed     Abstract available


  100. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    PubMed     Abstract available


    October 2023
  101. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    PubMed     Abstract available


  102. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    PubMed     Abstract available


  103. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    PubMed     Abstract available


  104. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    PubMed     Abstract available


  105. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    PubMed     Abstract available


  106. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    PubMed     Abstract available


  107. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    PubMed     Abstract available


    September 2023
  108. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    PubMed     Abstract available


  109. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    PubMed     Abstract available


  110. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    PubMed     Abstract available


    August 2023
  111. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    PubMed     Abstract available


  112. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    PubMed     Abstract available


    July 2023
  113. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    PubMed     Abstract available


    June 2023
  114. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    PubMed     Abstract available


  115. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    PubMed     Abstract available


  116. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    PubMed     Abstract available


  117. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    PubMed     Abstract available


  118. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    PubMed     Abstract available


  119. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    PubMed     Abstract available


    April 2023
  120. HUI P, Ni F, Zheng L, Jia L, et al
    Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
    BMC Cancer. 2023;23:355.
    PubMed     Abstract available


  121. TANG Y, Lei Y, Gao P, Jia J, et al
    Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
    BMC Cancer. 2023;23:328.
    PubMed     Abstract available


  122. YANG X, Zhang S, Cui Y, Li Y, et al
    Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:320.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum